Treats partial-onset seizures. ANDA 219241, held by Aurobindo Pharma Ltd. Oxcarbazepine.
As of Nov 16, 2026, ANDA 219241 (Oxcarbazepine), held by Aurobindo Pharma Ltd, was first approved by FDA on Apr 30, 2025, with 0 approved supplements and 0 published complete response letters.
Oxcarbazepine extended-release tablets are indicated for the treatment of partial-onset seizures in patients 6 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 30, 2025 | Original application | Approved | None posted |
| Oxcarbazepine150MG · tablet, extended release;oral | Oxcarbazepine | Rx |
| Oxcarbazepine300MG · tablet, extended release;oral | Oxcarbazepine | Rx |
| Oxcarbazepine600MG · tablet, extended release;oral | Oxcarbazepine | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters